
NASDAQ:HRMY
This summary was created by AI, based on 3 opinions in the last 12 months.
Harmony Biosciences Holdings Inc (HRMY) is a commercial stage pharmaceutical company that focuses on neurological treatments. The company's ongoing development pipeline is strong, particularly with its innovative histamine-focused foundation treatment and advancements in cannabis-based CBD gels aimed at treating narcolepsy. Despite some fluctuations in its stock price, the company maintains positive cash flow and growing cash reserves, while successfully retiring debt. Experts suggest trailing stop-loss adjustments to protect investments and have positive price targets that indicate substantial upside potential. Overall, HRMY appears to be well-positioned in its niche market.
Harmony Biosciences Holdings Inc is a American stock, trading under the symbol HRMY (previously HRMY-Q on Stockchase) on the NASDAQ (HRMY). It is usually referred to as NASDAQ:HRMY or HRMY
In the last year, 3 stock analysts issued a Buy, Sell, or Hold rating on HRMY (previously HRMY-Q on Stockchase). 3 analysts recommended to BUY and 0 analysts recommended to SELL the stock. The latest stock analyst rating is TOP PICK. Read the latest stock experts' ratings for Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc was recommended as a Top Pick by The Panic-Proof Portfolio (Stockchase Research) on 2025-07-17. Read the latest stock experts ratings for Harmony Biosciences Holdings Inc.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is covered by Stockchase experts and is worth watching.
On 2026-07-02, Harmony Biosciences Holdings Inc (HRMY) stock closed at a price of $37.58.
Our PAST TOP PICK with HRMY has triggered its stop at $33. To remain disciplined, we recommend covering the position at this time.